SGMO Share Price | Sangamo Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Sangamo Therapeutics, Inc.?

Market Cap: As of Jun 18, Sangamo Therapeutics, Inc. has a market capitalization of 118.55 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Sangamo Therapeutics, Inc. reported net sales of 63.76 million and a net profit of -80.75 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 22.77 million, while total assets were reported at 105.31 million.

Q: What does Sangamo Therapeutics, Inc. do?

Overview: Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic therapies that transform patients' lives within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 6 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -31 Million (Quarterly Results - Mar 2025) Market-cap: USD 118.55 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -5.13 Return on Equity: -1,621.75% Price to Book: 24.16Contact Details: Address: 7000 MARINA BLVD, BRISBANE CA: 94005 Tel: ['1 510 9706000', '1 510 2368951'] Fax: 1 302 6555049 Website: https://www.sangamo.com/

Q: Should I buy, sell or hold Sangamo Therapeutics, Inc.?

Based on the current analysis of Sangamo Therapeutics, Inc., the recommendation would be to hold your position in the stock. The company has shown positive results over the last three consecutive quarters, with net sales increasing significantly by 454.42%. However, despite this growth, the long-term outlook appears less favorable, as the operating profit has only grown at an annual rate of 4.15% over the past five years. Additionally, the company is reporting negative EBITDA and has a high operating cash flow deficit of USD -44.62 million, alongside a net profit of USD -53.7 million.While the stock has generated a return of 0% over the past year, its profits have risen by 64.1%, indicating some potential for improvement. The high institutional holdings at 45.93% suggest that knowledgeable investors are backing the company, which can be a positive sign.Given these factors, it may be prudent to hold your investment in Sangamo Therapeutics while monitoring its performance and market conditions closely.

Q: Is Sangamo Therapeutics, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for Sangamo Therapeutics, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearish momentum and a mixed signal from the MACD, which is mildly bullish on the weekly and monthly time frames. The Bollinger Bands show a bullish weekly trend but a mildly bearish monthly trend, while KST is mildly bullish weekly but mildly bearish monthly. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -46.08% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.38 M

Shareholding (Dec 2025)

FII

2.02%

Held by 55 FIIs

DII

84.47%

Held by 26 DIIs

Promoter

0.00%

How big is Sangamo Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Sangamo Therapeutics, Inc. has a market capitalization of 118.55 million, with net sales of 63.76 million and a net profit of -80.75 million over the last four quarters. The company's shareholder's funds are 22.77 million, and total assets are 105.31 million.

View full answer

What does Sangamo Therapeutics, Inc. do?

22-Jun-2025

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic therapies. As of March 2025, it reported net sales of $6 million and a net loss of $31 million, with a market cap of $118.55 million.

View full answer

Should I buy, sell or hold Sangamo Therapeutics, Inc.?

22-Jun-2025

Who are in the management team of Sangamo Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Sangamo Therapeutics, Inc. includes Dr. Alexander Macrae as President and CEO, with Dr. Kenneth Hillan and several independent directors: Mr. Robert Carey, Dr. John Markels, Mr. James Meyers, and Ms. H. Stewart Parker.

View full answer

Is Sangamo Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Sangamo Therapeutics, Inc. has shifted to a mildly bearish trend, influenced by daily moving averages and mixed signals from MACD, while significantly underperforming the S&P 500 with a year-to-date return of -46.08%.

View full answer

Compare Sangamo Therapeutics, Inc. with Similar Stocks

Sonnet BioTherapeutics Holdings, Inc.PepGen Inc.Theseus Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate -6.97% of over the last 5 years

The company has declared negative results in Jan 70 after 3 consecutive negative quarters

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 134 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-4.89

Return on Equity

-1,748.68%

Price to Book

21.47

Revenue and Profits:

Net Sales:

14 Million

(Quarterly Results - Dec 2025)

Net Profit:

-37 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-50.69%

6 Months

-68.38%

1 Year

-75.61%

2 Years

-68.05%

3 Years

-86.94%

4 Years

-96.12%

5 Years

-98.44%

Sangamo Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-25.91%

EBIT Growth (5y)

-6.97%

EBIT to Interest (avg)

-142.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.13

Sales to Capital Employed (avg)

3.12

Tax Ratio

0.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.56%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

21.47

EV to EBIT

-0.94

EV to EBITDA

-1.01

EV to Capital Employed

-4.26

EV to Sales

3.15

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1748.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 31 Schemes (13.5%)

Foreign Institutions

Held by 55 Foreign Institutions (2.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 2,266.67% vs -96.72% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -7.16% vs -74.50% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.20",
          "val2": "0.60",
          "chgp": "2,266.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.10",
          "val2": "-34.20",
          "chgp": "32.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.20",
          "val2": "0.60",
          "chgp": "-2,300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.40",
          "val2": "-34.90",
          "chgp": "-7.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,754.80%",
          "val2": "-62,142.90%",
          "chgp": "6,038.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -31.49% vs -67.20% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -25.54% vs 62.02% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "39.60",
          "val2": "57.80",
          "chgp": "-31.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-100.40",
          "val2": "-89.80",
          "chgp": "-11.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.20",
          "val2": "-5.90",
          "chgp": "-123.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-122.90",
          "val2": "-97.90",
          "chgp": "-25.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,730.70%",
          "val2": "-1,715.10%",
          "chgp": "-101.56%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

14.20

0.60

2,266.67%

Operating Profit (PBDIT) excl Other Income

-23.10

-34.20

32.46%

Interest

0.00

Exceptional Items

-13.20

0.60

-2,300.00%

Consolidate Net Profit

-37.40

-34.90

-7.16%

Operating Profit Margin (Excl OI)

-1,754.80%

-62,142.90%

6,038.81%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 2,266.67% vs -96.72% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -7.16% vs -74.50% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

39.60

57.80

-31.49%

Operating Profit (PBDIT) excl Other Income

-100.40

-89.80

-11.80%

Interest

0.00

Exceptional Items

-13.20

-5.90

-123.73%

Consolidate Net Profit

-122.90

-97.90

-25.54%

Operating Profit Margin (Excl OI)

-2,730.70%

-1,715.10%

-101.56%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -31.49% vs -67.20% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -25.54% vs 62.02% in Dec 2024

All Annual Results

Company CV

About Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Company Coordinates

Company Details

7000 MARINA BLVD , BRISBANE CA : 94005

Tel: 1 510 97060001 510 2368951

https://www.sangamo.com/

Registrar Details